# A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC

> **NCT00343291** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 121 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Cetuximab
- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00343291
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2010-05
- **Final completion:** 2010-12
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2011-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00343291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00343291, "A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00343291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*